Abbott (NYSE: ABT) announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease). Study results suggest that atrasentan, used in conjunction with renin-angiotensin system (RAS) inhibitors, may reduce albuminuria (presence of (more…)
Posts Tagged ‘Kidney’
Abbott Announces Positive Results From Phase 2 Study Of Low Dose Atrasentan For Treatment Of Diabetic Kidney Disease
Tuesday, November 23rd, 2010
Kidney Damage Heightens Mortality Risk
Friday, August 27th, 2010Minor kidney damage in people with type 1 diabetes dramatically increases the chances of premature death, a new study finds.
Diabetics presenting early and asymptomatic kidney damage, as manifested by trace amounts of protein in the urine, were six times likelier to die than the general population, according to the study, summarized at ScienceDaily.com. When the diabetics’ kidneys functioned normally over time, they were died (more…)
Aggressive Glucose Control in Patients With Diabetes and Kidney Disease Not Associated With Improved Survival
Wednesday, July 28th, 2010Aggressive control of glycosylated hemoglobin (HbA1c) levels in patients with diabetes and end-stage renal disease (ESRD) is not associated with lower mortality, according to research published in the Clinical Journal of the American Society of Nephrology.Â
Researchers from the Joslin Diabetes Center in Boston suggested that clinicians avoid aggressive glucose management and instead focus on the recommended HbA1c level of under 7 percent (more…)